Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| fosamprenavir/ritonavir (1400mg/100mg BID)NCT00144833 | GlaxoSmithKlinePHASE3 | TERMINATED Incomplete data | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-12 |
| fosamprenavir/ritonavir (700mg/100mg BID)NCT00144833 | GlaxoSmithKlinePHASE3 | TERMINATED Incomplete data | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-12 |
| pioglitazoneNCT00159211 | Assistance Publique - Hôpitaux de ParisNA | TERMINATED inclusion was finished | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-08 |
| UMULINE NPHNCT00159211 | Assistance Publique - Hôpitaux de ParisNA | TERMINATED inclusion was finished | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-08 |
| [S,S]-ReboxetineNCT00354094 | PfizerPHASE2 | TERMINATED The study was stopped due to business/operational issues. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-11-08 |
| ramipril-telmisartanNCT00208221 | Institut de Recherches Cliniques de MontrealPHASE3 | TERMINATED Not enough recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-08 |
| ramiprilNCT00208221 | Institut de Recherches Cliniques de MontrealPHASE3 | TERMINATED Not enough recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-08 |
| Triamcinolone Acetonide- Indomethacin-Cryotherapy-CastingNCT00554476 | Azad University of Medical SciencesPHASE4 | TERMINATED Because the sample volume was completed during three years. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-07 |
| Interferon gamma-1bNCT00076635 | InterMunePHASE3 | TERMINATED program discontinued based on GIPF-007 results | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| azathioprineNCT00052039 | InterMunePHASE3 | TERMINATED Study design changes were needed based on GIPF-001 results | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| interferon-gamma 1bNCT00052039 | InterMunePHASE3 | TERMINATED Study design changes were needed based on GIPF-001 results | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| XTL-2125NCT00255359 | Hadassah Medical OrganizationPHASE1 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| docetaxelNCT00273338 | NovaceaPHASE3 | TERMINATED DSMB | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| calcitriolNCT00273338 | NovaceaPHASE3 | TERMINATED DSMB | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| calcitriol + gemcitabine + erlotinibNCT00536770 | NovaceaPHASE2 | SUSPENDED DSMB | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| calcitriol + gemcitabineNCT00536770 | NovaceaPHASE2 | SUSPENDED DSMB | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| Humira (adalimumab)NCT00512863 | AbbottPHASE2 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-06 |
| 5-Fluorouracil, leucovorin, oxaliplatin, avastinNCT00385021 | Southwestern Regional Medical CenterPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-02 |
| late thermal cureNCT00348907 | Association Francaise pour la Recherche ThermalePHASE3 | TERMINATED decision to stop the study because of enrollment difficulties. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| thermal cureNCT00348907 | Association Francaise pour la Recherche ThermalePHASE3 | TERMINATED decision to stop the study because of enrollment difficulties. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| Synbiotic 2000NCT00164099 | Beth Israel Medical CenterPHASE4 | TERMINATED Patients would not take product | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| RituximabNCT00057447 | InterMunePHASE1, PHASE2 | TERMINATED administrative reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| Interferon Gamma-1bNCT00057447 | InterMunePHASE1, PHASE2 | TERMINATED administrative reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| interferon gamma-1bNCT00043355 | InterMunePHASE2 | TERMINATED Futility | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| S-1NCT00209677 | Hokkaido Gastrointestinal Cancer Study GroupPHASE1, PHASE2 | SUSPENDED Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in Japan. h | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |